| 2020 |
| 05/12 | 15:00 新中期経営計画 |
| 05/12 | 15:00 2020年3月期決算補足資料 |
| 05/12 | 15:00 2020年3月期決算短信〔日本基準〕(連結) |
| 05/12 | 2,651 | 2,662 | 2,552 | 2,573 | -1.49% | 66,700 | 1333億1017万 | +0.39% |
| 05/11 | 2,590 | 2,626 | 2,581 | 2,612 | -1.06% | 48,400 | 1353億3081万 | +1.87% |
| 05/08 | 2,635 | 2,668 | 2,597 | 2,640 | +1.77% | 79,200 | 1367億8152万 | +2.68% |
| 05/07 | 2,600 | 2,629 | 2,581 | 2,594 | -0.27% | 102,900 | 1343億9821万 | +0.46% |
| 05/01 | 2,573 | 2,627 | 2,573 | 2,601 | +1.6% | 96,800 | 1347億6089万 | +0.39% |
| 04/30 | 2,643 | 2,657 | 2,560 | 2,560 | -1.8% | 92,100 | 1326億3663万 | -1.16% |
| 04/28 | 2,566 | 2,617 | 2,540 | 2,607 | +1.48% | 90,400 | 1350億7175万 | +0.77% |
| 04/27 | 2,638 | 2,652 | 2,556 | 2,569 | -1.65% | 74,000 | 1331億293万 | -0.46% |
| 04/24 | 2,577 | 2,616 | 2,554 | 2,612 | +1.12% | 77,200 | 1353億3081万 | +1.48% |
| 04/23 | 2,555 | 2,583 | 2,527 | 2,583 | +1.97% | 59,500 | 1338億2829万 | +0.66% |
| 04/22 | 2,511 | 2,563 | 2,510 | 2,533 | +0.68% | 70,000 | 1312億3773万 | -0.71% |
| 04/21 | 2,501 | 2,548 | 2,485 | 2,516 | -0.67% | 67,900 | 1303億5694万 | -0.75% |
| 04/20 | 2,501 | 2,540 | 2,500 | 2,533 | -0.51% | 43,500 | 1312億3773万 | +0.64% |
| 04/17 | 2,573 | 2,576 | 2,503 | 2,546 | +0.39% | 71,600 | 1319億1127万 | +1.8% |
| 04/16 | 2,488 | 2,544 | 2,478 | 2,536 | +1.28% | 86,900 | 1313億9316万 | +1.85% |
| 04/15 | 2,499 | 2,527 | 2,485 | 2,504 | +0.16% | 140,900 | 1297億3520万 | +0.85% |
| 04/14 | 2,574 | 2,589 | 2,478 | 2,500 | -2.57% | 109,800 | 1295億2796万 | +0.81% |
| 04/13 | 2,600 | 2,616 | 2,558 | 2,566 | -2.62% | 35,200 | 1329億4750万 | +3.55% |
| 04/10 | 2,509 | 2,635 | 2,496 | 2,635 | +3.58% | 49,600 | 1365億2247万 | +6.34% |
| 04/09 | 2,561 | 2,587 | 2,496 | 2,544 | -2.15% | 64,600 | 1318億765万 | +2.62% |
| 04/08 | 2,575 | 2,630 | 2,525 | 2,600 | +0.12% | 163,200 | 1347億908万 | +4.71% |
| 04/07 | 2,568 | 2,608 | 2,527 | 2,597 | +2.28% | 72,100 | 1345億5364万 | +4.47% |
| 04/06 | 2,480 | 2,541 | 2,477 | 2,539 | +3.59% | 98,100 | 1315億4859万 | +1.93% |
| 04/03 | 2,526 | 2,557 | 2,409 | 2,451 | -2.89% | 69,700 | 1269億8921万 | -1.72% |
| 04/02 | 2,594 | 2,628 | 2,524 | 2,524 | -2.7% | 82,500 | 1307億7143万 | +0.76% |
| 04/01 | 2,736 | 2,801 | 2,589 | 2,594 | -6.72% | 82,300 | 1343億9821万 | +3.18% |
| 03/31 | 2,908 | 2,950 | 2,735 | 2,781 | -5.18% | 86,700 | 1440億8690万 | +10.31% |
| 03/30 | 2,814 | 2,949 | 2,756 | 2,933 | +3.93% | 109,100 | 1519億6220万 | +16.2% |
| 03/27 | 2,726 | 2,822 | 2,682 | 2,822 | +9.55% | 187,200 | 1462億1116万 | +11.94% |
| 03/27 | 9:00 膀胱がん用剤「CG0070(開発番号)」のライセンス契約締結に関するお知らせ |
| 03/26 | 2,453 | 2,605 | 2,368 | 2,576 | +3.7% | 121,000 | 1334億6561万 | +2.1% |
| 03/25 | 2,599 | 2,599 | 2,409 | 2,484 | +1.06% | 168,600 | 1286億9898万 | -1.97% |
| 03/24 | 2,464 | 2,532 | 2,397 | 2,458 | +3.06% | 139,400 | 1273億5189万 | -3.65% |
| 03/23 | 2,353 | 2,434 | 2,289 | 2,385 | -0.75% | 188,100 | 1235億6967万 | -7.27% |
| 03/19 | 2,315 | 2,431 | 2,259 | 2,403 | +8.24% | 144,700 | 1245億227万 | -7.4% |
| 03/18 | 2,165 | 2,293 | 2,130 | 2,220 | +4.13% | 190,000 | 1150億2083万 | -15.23% |
| 03/17 | 2,011 | 2,190 | 2,002 | 2,132 | +2.9% | 218,800 | 1104億6144万 | -19.61% |
| 03/16 | 2,139 | 2,172 | 2,069 | 2,072 | -2.4% | 107,900 | 1073億5277万 | -23% |
| 03/13 | 2,165 | 2,214 | 2,044 | 2,123 | -6.27% | 174,400 | 1099億9514万 | -22.29% |
| 03/12 | 2,322 | 2,337 | 2,259 | 2,265 | -4.11% | 124,200 | 1173億5233万 | -18.2% |
| 03/11 | 2,397 | 2,430 | 2,362 | 2,362 | -3.32% | 113,000 | 1223億7801万 | -15.61% |
| 03/10 | 2,424 | 2,556 | 2,308 | 2,443 | +0.33% | 97,100 | 1265億7472万 | -13.49% |
| 03/09 | 2,526 | 2,526 | 2,423 | 2,435 | -5.47% | 97,500 | 1261億6023万 | -14.59% |
| 03/06 | 2,622 | 2,624 | 2,566 | 2,576 | -3.45% | 87,500 | 1334億6561万 | -10.46% |
| 03/05 | 2,686 | 2,714 | 2,664 | 2,668 | +1.21% | 103,100 | 1382億3224万 | -7.9% |
| 03/04 | 2,631 | 2,693 | 2,629 | 2,636 | -1.68% | 81,000 | 1365億7428万 | -9.48% |
| 03/03 | 2,765 | 2,769 | 2,668 | 2,681 | -1.36% | 146,600 | 1389億578万 | -8.47% |
| 03/02 | 2,614 | 2,732 | 2,607 | 2,718 | +3.94% | 169,200 | 1408億2280万 | -7.71% |
| 02/28 | 2,661 | 2,687 | 2,593 | 2,615 | -3.54% | 125,000 | 1354億8624万 | -11.69% |
| 02/27 | 2,743 | 2,744 | 2,708 | 2,711 | -1.81% | 119,100 | 1404億6012万 | -9.06% |
| 02/26 | 2,734 | 2,772 | 2,707 | 2,761 | -0.07% | 116,400 | 1430億5068万 | -7.84% |
| 02/25 | 15:30 「ミニリンメルト」及び「デスモプレシン製剤」の国内販売権移管に関するお知らせ |
| 02/25 | 2,762 | 2,799 | 2,735 | 2,763 | -3.46% | 123,300 | 1431億5430万 | -8.18% |
| 02/21 | 2,845 | 2,877 | 2,834 | 2,862 | +0.14% | 51,700 | 1482億8361万 | -5.23% |
| 02/20 | 2,851 | 2,880 | 2,851 | 2,858 | -0.03% | 43,500 | 1480億7636万 | -5.61% |
| 02/19 | 2,900 | 2,907 | 2,859 | 2,859 | +0.32% | 69,900 | 1481億2817万 | -5.83% |
| 02/18 | 2,889 | 2,896 | 2,845 | 2,850 | -2.33% | 57,300 | 1476億6187万 | -6.37% |
| 02/17 | 2,963 | 2,963 | 2,907 | 2,918 | -2.24% | 38,300 | 1511億8503万 | -4.48% |
| 02/14 | 2,951 | 2,991 | 2,950 | 2,985 | +0.64% | 52,900 | 1546億5638万 | -2.55% |
| 02/13 | 2,960 | 2,974 | 2,911 | 2,966 | -0.74% | 39,000 | 1536億7197万 | -3.29% |
| 02/12 | 3,040 | 3,040 | 2,965 | 2,988 | -2.03% | 60,000 | 1548億1182万 | -2.77% |
| 02/10 | 3,080 | 3,095 | 3,050 | 3,050 | -2.09% | 47,400 | 1580億2411万 | -0.81% |
| 02/07 | 3,095 | 3,115 | 3,070 | 3,115 | +1.14% | 33,900 | 1613億9184万 | +1.2% |
| 02/06 | 3,080 | 3,105 | 3,075 | 3,080 | +0.82% | 77,500 | 1595億7844万 | 0% |
| 02/05 | 3,065 | 3,100 | 3,045 | 3,055 | +0.99% | 102,300 | 1582億8317万 | -0.91% |
| 02/04 | 2,986 | 3,050 | 2,986 | 3,025 | +1.58% | 106,600 | 1567億2883万 | -1.98% |
| 02/03 | 10:00 2型糖尿病治療薬「マリゼブ」の販売移管に関するお知らせ |
| 02/03 | 2,985 | 3,030 | 2,947 | 2,978 | -4.7% | 146,300 | 1542億9370万 | -3.66% |
| 01/31 | 15:00 2020年3月期第3四半期決算短信〔日本基準〕(連結) |
| 01/31 | 15:00 2020年3月期第3四半期決算補足資料 |
| 01/31 | 3,085 | 3,160 | 3,085 | 3,125 | +1.3% | 66,200 | 1619億995万 | +0.9% |
| 01/30 | 3,085 | 3,125 | 3,080 | 3,085 | +0.16% | 59,400 | 1598億3750万 | -0.39% |
| 01/29 | 3,060 | 3,090 | 3,050 | 3,080 | +1.15% | 57,200 | 1595億7844万 | -0.61% |
| 01/28 | 3,030 | 3,065 | 3,010 | 3,045 | -0.16% | 64,600 | 1577億6505万 | -1.81% |
| 01/27 | 3,030 | 3,075 | 3,025 | 3,050 | -0.97% | 45,000 | 1580億2411万 | -1.8% |
| 01/24 | 3,105 | 3,110 | 3,055 | 3,080 | -0.96% | 39,200 | 1595億7844万 | -0.87% |
| 01/23 | 3,140 | 3,140 | 3,095 | 3,110 | -0.64% | 39,100 | 1611億3278万 | +0.1% |
| 01/22 | 3,095 | 3,150 | 3,095 | 3,130 | +1.79% | 48,100 | 1621億6900万 | +0.81% |
| 01/21 | 3,070 | 3,100 | 3,070 | 3,075 | -0.65% | 21,800 | 1593億1939万 | -0.87% |
| 01/20 | 3,055 | 3,105 | 3,050 | 3,095 | +1.81% | 32,300 | 1603億5561万 | -0.19% |
| 01/17 | 3,065 | 3,070 | 3,030 | 3,040 | -0.33% | 32,700 | 1575億600万 | -2% |
| 01/16 | 3,080 | 3,090 | 3,050 | 3,050 | -0.16% | 36,800 | 1580億2411万 | -1.64% |
| 01/15 | 3,095 | 3,095 | 3,030 | 3,055 | -0.65% | 38,900 | 1582億8317万 | -1.42% |
| 01/14 | 3,140 | 3,145 | 3,065 | 3,075 | -1.76% | 55,200 | 1593億1939万 | -0.74% |
| 01/10 | 3,100 | 3,145 | 3,100 | 3,130 | +0.48% | 38,900 | 1621億6900万 | +1.13% |
| 01/09 | 3,125 | 3,165 | 3,085 | 3,115 | +1.3% | 37,300 | 1613億9184万 | +0.74% |
| 01/08 | 3,050 | 3,100 | 3,025 | 3,075 | -1.13% | 70,100 | 1593億1939万 | -0.42% |
| 01/07 | 3,070 | 3,120 | 3,065 | 3,110 | +2.3% | 46,700 | 1611億3278万 | +0.84% |
| 01/06 | 3,050 | 3,065 | 3,030 | 3,040 | -2.56% | 57,500 | 1575億600万 | -1.3% |
| 2019 |
| 12/30 | 3,155 | 3,155 | 3,100 | 3,120 | -2.04% | 43,400 | 1616億5089万 | +1.46% |
| 12/27 | 3,165 | 3,210 | 3,165 | 3,185 | +0.95% | 45,800 | 1650億1862万 | +3.85% |
| 12/26 | 3,115 | 3,155 | 3,115 | 3,155 | +0.8% | 37,500 | 1634億6428万 | +3.27% |
| 12/25 | 3,155 | 3,155 | 3,130 | 3,130 | -0.48% | 36,300 | 1621億6900万 | +2.83% |
| 12/24 | 3,130 | 3,160 | 3,120 | 3,145 | +0.96% | 31,500 | 1629億4617万 | +3.66% |
| 12/23 | 3,150 | 3,155 | 3,115 | 3,115 | -0.95% | 48,100 | 1613億9184万 | +3.08% |
| 12/20 | 3,115 | 3,155 | 3,075 | 3,145 | +0.48% | 130,500 | 1629億4617万 | +4.35% |
| 12/19 | 3,120 | 3,155 | 3,100 | 3,130 | +0.32% | 35,200 | 1621億6900万 | +4.26% |
| 12/18 | 3,160 | 3,160 | 3,090 | 3,120 | -1.89% | 64,200 | 1616億5089万 | +4.35% |
| 12/17 | 3,130 | 3,195 | 3,115 | 3,180 | +3.25% | 64,600 | 1647億5956万 | +6.71% |
| 12/16 | 3,085 | 3,115 | 3,075 | 3,080 | +0.33% | 62,400 | 1595億7844万 | +3.7% |
| 12/13 | 3,100 | 3,110 | 3,070 | 3,070 | +0.66% | 115,100 | 1590億6033万 | +3.58% |
| 12/12 | 3,085 | 3,095 | 3,050 | 3,050 | -0.81% | 57,100 | 1580億2411万 | +3.11% |
| 12/11 | 3,060 | 3,130 | 3,060 | 3,075 | +1.49% | 72,900 | 1593億1939万 | +4.2% |
| 12/10 | 3,055 | 3,105 | 3,020 | 3,030 | -3.04% | 118,500 | 1569億8789万 | +3.1% |
| 12/09 | 17:00 GnRHアンタゴニスト「リンザゴリクス(KLH-2109)」の海外における子宮筋腫を対象とした第3相臨床試験(PRIMROSE2試験)の中間解析結果について |
| 12/09 | 3,030 | 3,140 | 3,010 | 3,125 | +3.82% | 92,600 | 1619億995万 | +6.62% |
